Promising single-dose malaria treatment advances toward pan-African clinical trial

AI Summary

Researchers at the German Center for Infection Research have developed a promising single-dose malaria treatment called SPAP, aimed at combating drug resistance and simplifying treatment. The treatment is being prepared for extensive clinical trials across Africa, led in part by Prof. Ghyslain Mombo-Ngoma, recognized for his contributions to global health.

Researchers at the German Center for Infection Research (DZIF) have developed a promising single-dose malaria treatment that could help address growing drug resistance and simplify treatment for patients. The four-drug combination treatment, known as SPAP, is now being prepared for large-scale clinical testing across Africa. Prof. Ghyslain Mombo-Ngoma, who was named to the 2026 TIME100 Health list in recognition of his contributions to global health research, is co-leading the project.